138 related articles for article (PubMed ID: 34342378)
21. Derivation and validation of the CFracture competing risk fracture prediction tool compared with QFracture in older people and people with comorbidity: a population cohort study.
Livingstone SJ; Guthrie B; McMinn M; Eke C; Donnan PT; Morales DR
Lancet Healthy Longev; 2023 Jan; 4(1):e43-e53. PubMed ID: 36610448
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonate use and subsequent hip fracture in South Korea.
Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.
Robinson DE; Ali MS; Strauss VY; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey F; Cooper C; Dedman D; Delmestri A; Judge A; Javaid MK; Prieto-Alhambra D
Health Technol Assess; 2021 Mar; 25(17):1-106. PubMed ID: 33739919
[TBL] [Abstract][Full Text] [Related]
24. Assessing Risk of Osteoporotic Fractures in Primary Care: Development and Validation of the FRA-HS Algorithm.
Francesco L; Elisa B; Raffaella M; Alessandro P; Iacopo C; Giampiero M; Bruno F; Daniel PA; Luisa BM; Claudio C
Calcif Tissue Int; 2017 Jun; 100(6):537-549. PubMed ID: 28160026
[TBL] [Abstract][Full Text] [Related]
25. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos.
Fraser LA; Langsetmo L; Berger C; Ioannidis G; Goltzman D; Adachi JD; Papaioannou A; Josse R; Kovacs CS; Olszynski WP; Towheed T; Hanley DA; Kaiser SM; Prior J; Jamal S; Kreiger N; Brown JP; Johansson H; Oden A; McCloskey E; Kanis JA; Leslie WD;
Osteoporos Int; 2011 Mar; 22(3):829-37. PubMed ID: 21161508
[TBL] [Abstract][Full Text] [Related]
26. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
27. Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort.
Martínez-Laguna D; Tebé C; Nogués X; Kassim Javaid M; Cooper C; Moreno V; Diez-Perez A; Collins GS; Prieto-Alhambra D
PLoS One; 2018; 13(9):e0203533. PubMed ID: 30192850
[TBL] [Abstract][Full Text] [Related]
28. Prospective risk of osteoporotic fractures in patients with advanced chronic obstructive pulmonary disease.
Gupta A; Greening NJ; Evans RA; Samuels A; Toms N; Steiner MC
Chron Respir Dis; 2019; 16():1479972318769763. PubMed ID: 29661041
[TBL] [Abstract][Full Text] [Related]
29. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
[TBL] [Abstract][Full Text] [Related]
30. Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality.
Sing CW; Lin TC; Bartholomew S; Bell JS; Bennett C; Beyene K; Bosco-Levy P; Bradbury BD; Chan AHY; Chandran M; Cooper C; de Ridder M; Doyon CY; Droz-Perroteau C; Ganesan G; Hartikainen S; Ilomaki J; Jeong HE; Kiel DP; Kubota K; Lai EC; Lange JL; Lewiecki EM; Lin J; Liu J; Maskell J; de Abreu MM; O'Kelly J; Ooba N; Pedersen AB; Prats-Uribe A; Prieto-Alhambra D; Qin SX; Shin JY; Sørensen HT; Tan KB; Thomas T; Tolppanen AM; Verhamme KMC; Wang GH; Watcharathanakij S; Wood SJ; Cheung CL; Wong ICK
J Bone Miner Res; 2023 Aug; 38(8):1064-1075. PubMed ID: 37118993
[TBL] [Abstract][Full Text] [Related]
31. Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM).
Möller S; Skjødt MK; Yan L; Abrahamsen B; Lix LM; McCloskey EV; Johansson H; Harvey NC; Kanis JA; Rubin KH; Leslie WD
Osteoporos Int; 2022 Jan; 33(1):57-66. PubMed ID: 34596704
[TBL] [Abstract][Full Text] [Related]
32. Does the SORG Orthopaedic Research Group Hip Fracture Delirium Algorithm Perform Well on an Independent Intercontinental Cohort of Patients With Hip Fractures Who Are 60 Years or Older?
Oosterhoff JHF; Oberai T; Karhade AV; Doornberg JN; Kerkhoffs GMMJ; Jaarsma RL; Schwab JH; Heng M
Clin Orthop Relat Res; 2022 Nov; 480(11):2205-2213. PubMed ID: 35561268
[TBL] [Abstract][Full Text] [Related]
33. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
[TBL] [Abstract][Full Text] [Related]
34. A Risk Assessment Tool for Predicting Fragility Fractures and Mortality in the Elderly.
Tran T; Bliuc D; Pham HM; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser SM; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
J Bone Miner Res; 2020 Oct; 35(10):1923-1934. PubMed ID: 32460361
[TBL] [Abstract][Full Text] [Related]
35. Current approaches to secondary prevention after hip fracture in England and Wales - an analysis of trends between 2016 and 2020 using the National Hip Fracture Database (NHFD).
Mohsin Z; Javaid MK; Johansen A
Arch Osteoporos; 2023 Jul; 18(1):93. PubMed ID: 37428295
[TBL] [Abstract][Full Text] [Related]
36. Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures.
Aguado-Maestro I; Panteli M; García-Alonso M; Bañuelos-Díaz A; Giannoudis PV
Injury; 2017 Dec; 48 Suppl 7():S27-S33. PubMed ID: 28851521
[TBL] [Abstract][Full Text] [Related]
37. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study.
Kim SC; Kim MS; Sanfélix-Gimeno G; Song HJ; Liu J; Hurtado I; Peiró S; Lee J; Choi NK; Park BJ; Avorn J
Am J Med; 2015 May; 128(5):519-26.e1. PubMed ID: 25660252
[TBL] [Abstract][Full Text] [Related]
38. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Pazianas M; Abrahamsen B; Wang Y; Russell RG
Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
[TBL] [Abstract][Full Text] [Related]
39. Validated risk rule using computerized data to identify males at high risk for fracture.
LaFleur J; Nelson RE; Yao Y; Adler RA; Nebeker JR
Osteoporos Int; 2012 Mar; 23(3):1017-27. PubMed ID: 21562876
[TBL] [Abstract][Full Text] [Related]
40. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
